On September 29, 2014, Daiichi Sankyo agreed to acquire Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound quizartinib.
In September 2014, Daiichi Sankyo purchased Ambit Biosciences for a sum of $410 million. This acquisition gave Daiichi access to quizartinib, a promising cancer treatment in its Phase III stage.